These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2872816)

  • 1. Rationale for the administration of opiate antagonists in treating infantile autism.
    Deutsch SI
    Am J Ment Defic; 1986 May; 90(6):631-5. PubMed ID: 2872816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior.
    Konicki PE; Schulz SC
    Psychopharmacol Bull; 1989; 25(4):556-63. PubMed ID: 2698484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Opiate hypothesis of the origin of early childhood autism and sequelae for psychopharmacotherapy].
    Lensing P; Klingler D; Panksepp J; Huber M; Saria A; Hackenberg B; Adam H
    Z Kinder Jugendpsychiatr; 1992 Sep; 20(3):185-96. PubMed ID: 1329399
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of atypical antipsychotics in the treatment of autistic disorder.
    Stachnik JM; Nunn-Thompson C
    Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians.
    Gillberg C
    Dev Med Child Neurol; 1995 Mar; 37(3):239-45. PubMed ID: 7890130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder.
    Elchaar GM; Maisch NM; Augusto LM; Wehring HJ
    Ann Pharmacother; 2006 Jun; 40(6):1086-95. PubMed ID: 16735648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of naltrexone on automutilation behavior in autistic psychosis].
    Decocq G; Kandelaft N; Compagnon M
    Presse Med; 1996 Feb; 25(7):305. PubMed ID: 8685173
    [No Abstract]   [Full Text] [Related]  

  • 9. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone.
    Scifo R; Cioni M; Nicolosi A; Batticane N; Tirolo C; Testa N; Quattropani MC; Morale MC; Gallo F; Marchetti B
    Ann Ist Super Sanita; 1996; 32(3):351-9. PubMed ID: 9028057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-endorphin disregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis.
    Sandman CA
    Synapse; 1988; 2(3):193-9. PubMed ID: 2463689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy for self mutilators. Remarks and prospects].
    Basquin M
    Neuropsychiatr Enfance Adolesc; 1984 Apr; 32(4):209-12. PubMed ID: 6146943
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of risperidone in children with autism spectrum disorder.
    Chavez B; Chavez-Brown M; Rey JA
    Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of narcotic antagonists on self-injurious behavior: a single case study.
    Bernstein GA; Hughes JR; Mitchell JE; Thompson T
    J Am Acad Child Adolesc Psychiatry; 1987 Nov; 26(6):886-9. PubMed ID: 3429408
    [No Abstract]   [Full Text] [Related]  

  • 15. [An approach to the pharmacological treatment of autism].
    Ruggieri VL
    Rev Neurol; 1996 Nov; 24(135):1451-5. PubMed ID: 8974754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone in children with autism.
    Buitelaar JK; Willemsen-Swinkels S; Van Engeland H
    J Am Acad Child Adolesc Psychiatry; 1998 Aug; 37(8):800-2. PubMed ID: 9695440
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis.
    Barrett RP; Feinstein C; Hole WT
    Am J Ment Retard; 1989 May; 93(6):644-51. PubMed ID: 2655671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
    Dodman NH; Shuster L; Court MH; Patel J
    J Am Vet Med Assoc; 1988 Jun; 192(11):1585-6. PubMed ID: 3410777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.